Pyridoxine-5′-phosphate oxidase (Pnpo) deficiency: Clinical and biochemical alterations associated with the C.347g > A (P.•Arg116gln) mutation

被引:30
作者
di Salvo, Martino L. [1 ]
Mastrangelo, Mario [2 ]
Nogues, Isabel [3 ]
Tolve, Manuela [4 ]
Paiardini, Alessandro [5 ]
Carducci, Carla [4 ]
Mei, Davide [6 ]
Montomoli, Martino [6 ]
Tramonti, Angela [7 ]
Guerrini, Renzo [6 ]
Contestabile, Roberto [1 ]
Leuzzi, Vincenzo [2 ]
机构
[1] Sapienza Univ Roma, Dipartimento Sci Biochim A Rossi Fanelli, Rome, Italy
[2] Sapienza Univ Roma, Dipartimento Pediat & Neuropsichiatria Infantile, Rome, Italy
[3] CNR, Ist Biol Ambientale & Forestale, Rome, Italy
[4] Sapienza Univ Roma, Dipartimento Med Sperimentale, Rome, Italy
[5] Sapienza Univ Roma, Dipartimento Biol & Biotecnol Charles Darwin, Rome, Italy
[6] Univ Firenze, Azienda Osped Univ Meyer, Dipartimento Neurosci, Florence, Italy
[7] CNR, Ist Biol & Patol Mol, Rome, Italy
关键词
Pyridoxal-5 '-phosphate oxidase deficiency; Vitamin B-6; Pyridoxal-5 '-phosphate; Epilepsy; Vitamin dependent epilepsies; Children; PYRIDOXINE 5'-PHOSPHATE OXIDASE; NEONATAL EPILEPTIC ENCEPHALOPATHY; PYRIDOXAL-5'-PHOSPHATE; RESPONSIVENESS; MECHANISM; GENE;
D O I
10.1016/j.ymgme.2017.08.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pyridoxal-5'-phosphate oxidase (PNPO) deficiency presents as a severe neonatal encephalopathy responsive to pyridoxal-5'-phosphate (PLP) or pyridoxine. Recent studies widened the phenotype of this condition and detected genetic variants on PNPO gene whose pathogenic role and clinical expression remain to be established. Objective: This paper aims to characterize the functional effects of the c.347G > A (p.Arg116Gln) mutation in the PNPO gene in order to define its pathogenicity and describe the clinical features of new patients with epilepsy carrying this mutation. Methods: Arg116Gln protein variant was expressed as recombinant protein. The mutant protein was characterized with respect to structural and kinetic properties, thermal stability, binding constants of cofactor (FMN) and product (PLP). We also reviewed clinical data of 3 new patients carrying the mutation. Results: The Arg116Gln mutation does not alter the overall enzyme structure and only slightly affects its catalytic efficiency; nevertheless, this mutation affects thermal stability of PNPO, reduces its affinity for FMN and impairs transfer of PLP to PLP-dependent enzymes. Three boys with seizure onset between 8 months and 3 years of age, carrying the Arg116Gln mutation, are described. These three patients exhibited different seizure types associated with interictal EEG abnormalities and slow background activity. Mild/moderate intellectual disability was observed in 2/3 patients. A dramatic therapeutic response to pyridoxine was observed in the only patient who still had active seizures when starting treatment, while in all three patients interictal EEG discharges and background activity improved after pyridoxine treatment was initiated. Conclusions: The reported data support a pathogenic role of the c.347G > A (p.Arg116Gln) mutation in PNPO deficiency. The later onset of symptoms and the milder epilepsy phenotype of these expand the disease phenotype.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 22 条
[1]  
[Anonymous], DISORDERS NEUROTRANS
[2]   B6-responsive disorders:: A model of vitamin dependency [J].
Clayton, PT .
JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 (2-3) :317-326
[3]   Neonatal epileptic encephalopathy [J].
Clayton, PT ;
Surtees, RAH ;
DeVile, C ;
Hyland, K ;
Heales, SJR .
LANCET, 2003, 361 (9369) :1614-1614
[4]   Expression, purification, and characterization of recombinant Escherichia coli pyridoxine 5′-phosphate oxidase [J].
Di Salvo, M ;
Yang, E ;
Zhao, G ;
Winkler, ME ;
Schirch, V .
PROTEIN EXPRESSION AND PURIFICATION, 1998, 13 (03) :349-356
[5]   Vitamin B6 salvage enzymes: Mechanism, structure and regulation [J].
di Salvo, Martino Luigi ;
Contestabile, Roberto ;
Safo, Martin K. .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2011, 1814 (11) :1597-1608
[6]   Structure and mechanism of Escherichia coli pyridoxine 5′-phosphate oxidase [J].
di Salvo, ML ;
Safo, MK ;
Musayev, FN ;
Bossa, F ;
Schirch, V .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2003, 1647 (1-2) :76-82
[7]  
DiSalvo M. L., 2017, DATA BRIEF UNPUB
[8]   Inactive mutants of human pyridoxine 5-phosphate oxidase: a possible role for a noncatalytic pyridoxal 5-phosphate tight binding site [J].
Ghatge, Mohini S. ;
Karve, Sayali S. ;
David, Tanya M. S. ;
Ahmed, Mostafa H. ;
Musayev, Faik N. ;
Cunningham, Kendra ;
Schirch, Verne ;
Safo, Martin K. .
FEBS OPEN BIO, 2016, 6 (05) :398-408
[9]  
Hatch J, 2016, JIMD REP, V26, P91, DOI 10.1007/8904_2015_482
[10]   Pyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation [J].
Jaeger, B. ;
Abeling, N. G. ;
Salomons, G. S. ;
Struys, E. A. ;
Simas-Mendes, M. ;
Geukers, V. G. ;
Poll-The, B. T. .
MOLECULAR GENETICS AND METABOLISM REPORTS, 2016, 6 :60-63